

President

Matthias G. von Herrath, MD
La Jolla Institute for Allergy and Immunology

Past President

Steven M. Holland, MD
National Institute of Allergy and Infectious
Diseases, NIH

President-Elect

Lawrence B. Schwartz, MD PhD
Virginia Commonwealth University

Secretary-Treasurer

Daniel C. Adelman, MD
University of California, San Francisco

Elected Councilors

John M. Routes, MD
Medical College of Wisconsin

Donald B. Kohn, MD
University of California, Los Angeles

Luigi D. Notarangelo, MD PhD
Children's Hospital Boston
Harvard Medical School

Appointed Councilors

Antonio Condino-Neto, MD PhD
University of São Paulo

Toshinori Nakayama, MD PhD
Chiba University

Hideho Okada, MD PhD
University of Pittsburgh Cancer Institute

Jordan S. Orange, MD PhD
Children's Hospital of Philadelphia

Troy R. Torgerson, MD PhD
University of Washington

Website Medical Editor

Robert A. Eisenberg, MD
University of Pennsylvania

December 5, 2011

Allen F. Wise
Chief Executive Officer
Coventry Health Care
6705 Rockledge Drive
Suite 990
Bethesda, MD 20817

Dear Mr. Wise,


We are writing in response to the recent policy change of Coventry – HealthAmerica adopting a "Fail First" single brand restrictive formulary policy for IVIG treatments. These treatments are necessary for the health of the patients covered by Coventry's insurance plan.

We as experts in clinical immunology agree with research conducted by the Immune Deficiency Foundation (IDF) which shows evidence that changing a patient's IG products can have many serious side effects and/or adverse reactions. The strong potential for these side effects and reactions requires additional infusion time and monitoring of the patient. The Clinical Immunology Society also supports IDF's Medical Advisory Resolution regarding formulary changes, which states that restricting patients' access to IG products poses an unjustified risk to patient safety.


The Clinical Immunology Society (CIS) strongly feels that your recent policy change is not in line with best practices in medicine and it is not what is best for the patient. The leadership of CIS strongly urges you to reverse this policy decision in the best interest of the patients you serve.

Thank you for your consideration of our informed, expert medical opinion.

Sincerely,



Jordan Orange, MD PhD
Chair, CIS Advocacy Committee



Matthias von Herrath, MD
CIS President

cc: David Fields
CEO Health America

Patricia P. Mueller, MD
Coventry Health Care

Lawrence Schwartz, MD PhD
Virginia Commonwealth University

John Routes, MD
Medical College of Wisconsin

Anne Krolikowski, CAE
CIS Executive Director